20 / 30
Overall Survival
:
RPSFT-adjusted Updated Analysis
Updated analysis: 15 Jun 2014.
Number of subjects at risk:
Lenvatinib 261 248 239 230 218 210 202 194 186 177 173 108 73 51 30 15
4
0
Placebo
131 126 118 106 58 15
7
7
6
6
5
4
3
1
1
0
0
0
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Overall Survival
Time (months)
0
2
4
6
8 10 12 14 16 18 20 22 24 26 28 30 32 34
Adjusted
P
-value: 0.005
Adjusted Hazard Ratio (95% CI): 0.53 (0.34–0.82)
Median (months) (95% CI)
Lenvatinib
NE (30.9–NE)
Placebo
19.1 (14.3–NE)